{"id":5739,"date":"2026-10-14T08:23:02","date_gmt":"2026-10-14T02:53:02","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/"},"modified":"2026-10-14T10:33:27","modified_gmt":"2026-10-14T05:03:27","slug":"alkem-share-price-today-2026-10-14","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/","title":{"rendered":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ALKEM<\/strong> \u00b7 14 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b95,232.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.34%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b95,250.00 \/ \u20b95,210.50<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b95,250.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>4,656<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>14 October 2026 \u00b7 09:45 AM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Alkem Laboratories Ltd. shares edged lower during Tuesday&#x27;s session, trading down 0.34% to close at \u20b95,232.00 compared to its previous close of \u20b95,250.00. The stock hovered near the lower end of its intraday range, moving between a high of \u20b95,250.00 and a low of \u20b95,210.50.<\/li>\n<li>Alkem Laboratories announced the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel of the company, effective October 12, 2026. The regulatory disclosures outline standard corporate governance updates filed via the NSE.<\/li>\n<li>Trading volume was 0.03 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Alkem Laboratories share price falling on 14 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Alkem Laboratories Ltd. shares edged lower during Tuesday&#x27;s session, trading down 0.34% to close at \u20b95,232.00 compared to its previous close of \u20b95,250.00. The stock hovered near the lower end of its intraday range, moving between a high of \u20b95,250.00 and a low of \u20b95,210.50.<\/p>\n<p class=\"wt-copy\">The broader market showed mixed tendencies as the Nifty index gained 0.13%, whereas pharmaceutical sector peers faced selling pressure with the Nifty Pharma sector benchmark falling 1.03%. Alkem&#x27;s performance reflected this sector-wide weakness, sliding alongside healthcare peers while experiencing a continuation of its recent consolidation phase, which includes a 5-day return of -2.21% contrasting with a 20-day gain of 1.38%.<\/p>\n<p class=\"wt-copy\">On the corporate front, recent filings highlight the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel effective October 12, 2026, though executive appointments of this nature typically provide structural governance context rather than directly driving daily price movements.<\/p>\n<p class=\"wt-copy\">4,656 shares traded by 14 October 2026 \u00b7 09:45 AM IST. This compares with a 20-day average daily volume of 1.72 lakh shares (0.03 times). The five-day average daily volume was 1.73 lakh shares. Separately, the NSE report for 13 October 2026 showed 59,517 shares delivered, representing 57.74% of that day\u2019s traded volume. The same report recorded 11,509 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector-led drift amid muted cash volumes<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s minor decline of 0.34% aligns with broader weakness across pharmaceutical peers, with Nifty Pharma shedding 1.03%. In the absence of direct same-day catalysts, the price action appears consistent with sector-wide profit-taking and low-turnover consolidation.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment of Senior Management Personnel<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem Laboratories announced the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel of the company, effective October 12, 2026. The regulatory disclosures outline standard corporate governance updates filed via the NSE.<\/p>\n<p class=\"wt-copy\">Board and management updates reflect organizational continuity and execution oversight, though they do not directly dictate short-term share price fluctuations.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Launch of NeuCeno (cenobamate) for Partial-Onset Seizures<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced the commercial launch of NeuCeno (cenobamate), a pharmaceutical product aimed at treating partial-onset seizures in adult patients in India. The rollout expands Alkem&#x27;s specialized central nervous system therapeutic portfolio.<\/p>\n<p class=\"wt-copy\">Product launches in specialized segments contribute to long-term revenue diversification and strengthen the company&#x27;s domestic franchise positioning.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Launch of Renocia Exo Hair Growth Serum<\/div>\n<div class=\"wt-card-date\">8 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem Laboratories introduced Renocia Exo, described as India&#x27;s first patented Ginsenoside Exosome-based hair growth serum. The specialized dermatology product targets the expanding domestic aesthetic and therapeutic hair-care market.<\/p>\n<p class=\"wt-copy\">Expands the company&#x27;s footprint into advanced exosome-based dermatological formulations, enhancing its consumer health and specialty product mix.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company w.e.f. October 12, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 16, 2026, titled &quot;Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">49.70%<\/div>\n<div class=\"wt-note\">51.20% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.42%<\/div>\n<div class=\"wt-note\">10.16% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">33.05%<\/div>\n<div class=\"wt-note\">31.56% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 29 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund &#8211; Hdfc Mid-Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">57.07 lakh shares \u00b7 4.77%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Multi-Asset Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">42.68 lakh shares \u00b7 3.57%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Large &amp; Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">23.83 lakh shares \u00b7 1.99%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">17 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b95,770.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a Neutral stance with a target price of \u20b95,770 following solid quarterly earnings performance, balancing growth visibility against current valuations.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JAYANTI SINHA<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 12.38 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 9.04 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SAMPRADA&amp;NANHAMATI SINGH FAMILY TRUST<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 5.50 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.10 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress and prescription uptake of newly launched specialty products like NeuCeno and Renocia Exo<\/li>\n<li>Delivery volume trends relative to the 57.74% delivery percentage recorded in the cash segment<\/li>\n<li>Broader Nifty Pharma sector momentum and relative outperformance against benchmark healthcare indices<\/li>\n<li>Upcoming quarterly financial results and management commentary on domestic margin expansion<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-13\/\">Alkem Laboratories in Focus After Senior Management Appointments | 13 October 2026 \u2014 13 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-07\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Rising 1.11% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-01\/\">Why Alkem Laboratories Shares Fell 2.24% Today: Sector Trends in Focus | 1 October 2026 \u2014 1 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/alkem\/\">More Alkem Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Alkem Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Alkem Laboratories announced the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel of the company, effective October 12, 2026. The regulatory disclosures outline standard corporate governance updates filed via the NSE.<\/p>\n<h3>How strong was Alkem Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">4,656 shares traded, 0.03 times the 20-day average daily volume. The price and volume data are dated 14 October 2026 \u00b7 09:45 AM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/\"}, \"headline\": \"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026\", \"description\": \"Alkem Laboratories share price fell 0.34% to \u20b95,232.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-14T02:53:02Z\", \"dateModified\": \"2026-10-14T10:33:19.518967+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/alkem-company-news-2026-10-14.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Appointment\",\"summary\":\"Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company w.e.f. October 12, 2026.\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 16:09:41\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"disclosure_text\":\"12th October, 2026 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM Sub: Disclosure under Regulation 30( 2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (\u201cSEBI LODR Regulations\u201d): Appointment of Senior Management Personnels Dear Sir(s)\/Madam, Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that Mr. Laxmikant Tiwari and Mr. Nilesh Vartak have been appointed at senior management position in the Company effective from 12th October, 2026. Further, the details as required in terms of Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing HO\/49\/14\/14(7)2025 - CFDPOD2\/I\/3762\/2026 dated January 30, 2026 are provided in Annexure I to this letter. The above information is also available on the website of the Company www.alkemlabs.com. Kindly take the same on your records. Sincerely, For Alkem Laboratories Limited Manish Narang President \u2013 Legal, Company Secretary and Compliance Officer Encl: a\/a Annexure I Sr. No. Particulars Details 1. Name Mr. Laxmikant Tiwari Mr. Nilesh Vartak 2. Reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise Appointment Appointment 3. Date of appointment\/ re-appointment\/ cessation (as applicable) and term of appointment\/ reappointment Date of appointment: 12th October, 2026 Term of Appointment: Duration of the contract shall be so long as he is in employment of the Company. Date of appointment: 12th October, 2026 Term of Appointment: Duration of the contract shall be so long as he is in employment of the Company. 4. Brief Profiles Mr. Laxmikant Tiwari is an experienced pharmaceutical operations executive with 27+ years of experience. He holds a MBA in Operations Management and Bachelors degree in Pharmacy. Mr. Nilesh Vartak has over 24 years of experience in supply chain leadership across the pharmaceutical\/healthcare, and consumer goods sectors. He holds a MBA in Finance and Bachelors degree in Marine Engineering. 5. Disclosure of relationships between directors Not Applicable Not Applicable\"}],\"recent_news\":[{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"12-Oct-2026 16:09:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5},{\"summary\":\"Appointment of Mr Nilesh Vartak as Senior Management Personnel of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"12-Oct-2026 16:09:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160911_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"An NSE promoter pledge\/encumbrance filing was identified, but the available filing text could not be reduced reliably to a concise current pledge figure.\",\"events\":[{\"summary\":\"le Marg, Worli, Mumbai - 400030 National Stock Exchange of India Limited \\\"Exchange Plaza\\\", 5th Floor, Plot No. C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 051 Symbol: ALKEM Sub: Declaration pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir\/ Madam, Pmsuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeove rs) Regulations, 2011, I, Basudeo N. Singh, promoter of Alkem Laboratories Limited, on behalf of all promoters\/ members of promoters group along with person acting in concert, hereby declare that we have not mad e any encumbrance, directly or indirectly, during the finan cial year 2025-26. The above is for your information and record. Thanking You Yours Sincerely, For and on behalf of Promot er(s) of Alkem Laboratories Limited ~(\\\\),?<:~\/ Basudeo N. Singh Promoter CC: Audit Committee Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013 Maharashtra, India\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"07-Apr-2026 14:30:02\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_06042026134202_Reg_3.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":49.7,\"public_pct\":50.3,\"fii_pct\":10.42,\"dii_pct\":22.63,\"mf_pct\":16.71,\"institutional_pct\":33.05,\"noninst_pct\":17.25,\"mf_scheme_count\":29,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund - Hdfc Mid-Cap Fund\",\"shares\":5706750,\"pct\":4.77},{\"name\":\"Icici Prudential Multi-Asset Fund\",\"shares\":4268472,\"pct\":3.57},{\"name\":\"Sbi Large &amp; Midcap Fund\",\"shares\":2383162,\"pct\":1.99},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":2234434,\"pct\":1.87},{\"name\":\"Dsp Midcap Fund\",\"shares\":2132118,\"pct\":1.78}],\"period\":\"30-JUN-2026\",\"submission_date\":\"09-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":51.2,\"previous_fii_pct\":10.16,\"previous_dii_pct\":21.4,\"previous_mf_pct\":15.57,\"previous_institutional_pct\":31.56,\"previous_mf_scheme_count\":30,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"5770\",\"view_summary\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why NDTV Profit\",\"headline\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why\",\"published\":\"2026-08-17T07:00:00+00:00\",\"source\":\"NDTV Profit\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"JAYANTI SINHA\",\"side\":\"Sell\",\"quantity\":\"12,38,220\",\"price\":\"5,200\",\"value\":\"\u20b9643.87 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"ICICI PRUDENTIAL MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"9,03,527\",\"price\":\"5,200\",\"value\":\"\u20b9469.83 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SAMPRADA&NANHAMATI SINGH FAMILY TRUST\",\"side\":\"Sell\",\"quantity\":\"5,50,000\",\"price\":\"5,200\",\"value\":\"\u20b9286.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"HDFC MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"5,09,615\",\"price\":\"5,200\",\"value\":\"\u20b9265.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"DSP MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"86,538\",\"price\":\"5,200\",\"value\":\"\u20b945.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SOCIETE GENERALE\",\"side\":\"Buy\",\"quantity\":\"48,090\",\"price\":\"5,200\",\"value\":\"\u20b925.01 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Nippon India Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Morgan Stanley Asia Singapore Pte\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alkem Laboratories share price fell 0.34% to \u20b95,232.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":5738,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026","_witty_meta_description":"Alkem Laboratories share price fell 0.34% to \u20b95,232.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Alkem Laboratories share price today","_witty_reason_label":"Sector-led drift amid muted cash volumes","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[143],"class_list":["post-5739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-alkem"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=5739"}],"version-history":[{"count":2,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5739\/revisions"}],"predecessor-version":[{"id":5899,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5739\/revisions\/5899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/5738"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=5739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=5739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=5739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}